SEARCH

SEARCH BY CITATION

References

  • 1
    Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007; 120: 151157
  • 2
    Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 5056
  • 3
    Montague DK, Jarow JP, Broderick GA et al. The management of erectile dysfunction: an update. Am Urol Assoc 2007; Chapter 1–5. Available at: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=ed. Accessed May 2012
  • 4
    Kimura M, Bañez LL, Schroeck FR et al. Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy. J Sex Med 2011; 8: 29352943
  • 5
    Laumann EO, Nicolosi A, Glasser DB et al. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 2005; 17: 3957
  • 6
    Kirby MG, Schnetzler G, Zou KH, Symonds T. Prevalence and detection rate of underlying disease in men with erectile dysfunction receiving phosphodiesterase type 5 inhibitors in the United Kingdom: a retrospective database study. Int J Clin Pract 2011; 65: 797806
  • 7
    Batty GD, Li Q, Czernichow S et al. Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial. J Am Coll Cardiol 2010; 56: 19081913
  • 8
    Navaneethan SD, Vecchio M, Johnson DW et al. Prevalence and correlates of self-reported sexual dysfunction in CKD: a meta-analysis of observational studies. Am J Kidney Dis 2010; 56: 670685
  • 9
    Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004; 171: 23412345
  • 10
    Burchardt M, Burchardt T, Baer L et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000; 164: 11881191
  • 11
    Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294: 29963002
  • 12
    Chew KK, Finn J, Stuckey B et al. Erectile dysfunction as a predictor for subsequent atherosclerotic cardiovascular events: findings from a linked-data study. J Sex Med 2010; 7: 192202
  • 13
    Eaton CB, Liu YL, Mittleman MA, Miner M, Glasser DB, Rimm EB. A retrospective study of the relationship between biomarkers of atherosclerosis and erectile dysfunction in 988 men. Int J Impot Res 2007; 19: 218225
  • 14
    Fung MM, Bettencourt R, Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo study. J Am Coll Cardiol 2004; 43: 14051411
  • 15
    Mulhall J, Teloken P, Brock G, Kim E. Obesity, dyslipidemias and erectile dysfunction: a report of a subcommittee of the Sexual Medicine Society of North America. J Sex Med 2006; 3: 778786
  • 16
    Riedner CE, Rhoden EL, Ribeiro EP, Fuchs SC. Central obesity is an independent predictor of erectile dysfunction in older men. J Urol 2006; 176: 15191523
  • 17
    Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000; 56: 302306
  • 18
    Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 5461
  • 19
    Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 2000; 163: 460463
  • 20
    Lewis RW, Fugl-Meyer KS, Corona G et al. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med 2010; 7: 15981607
  • 21
    Hatzimouratidis K, Amar E, Eardley I et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010; 57: 804814
  • 22
    Eli Lilly and Company. Cialis (Package Insert). Indianapolis, IN: Eli Lilly and Company, 2011
  • 23
    Bayer HealthCare Pharmaceuticals. Levitra (Package Insert). Wayne, NJ: Bayer HealthCare Pharmaceuticals, 2011
  • 24
    Pfizer Labs. Viagra (Package Insert). New York, NY: Pfizer Labs, 2010
  • 25
    VIVUS Inc. STENDRA (Package Insert). Mountain View, CA, USA: VIVUS Inc, 2012
  • 26
    Allison M, Grant T, Obaidi M, Marenco T, Yee S, Day WW. Pharmacokinetics of avanafil, a novel, rapidly absorbed, selective PDE5 inhibitor for the treatment of mild to severe erectile dysfunction (ED). J Sex Med 2011; 8: S466467
  • 27
    Kotera J, Mochida H, Inoue H et al. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Urol 2012; June 14 [Epub ahead of print]
  • 28
    International Conference on Harmonisation. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Available at: http://www.ich.org/products/guidelines.html. Accessed May 2012
  • 29
    World Medical Association General Assembly. WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net/en/30publications/10policies/b3/. Accessed May 2012
  • 30
    Gingell C, Sultana SR, Wulff MB, Gepi-Attee S. Duration of action of sildenafil citrate in men with erectile dysfunction. J Sex Med 2004; 1: 179184
  • 31
    Klotz T, Sachse R, Heidrich A et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001; 19: 3239
  • 32
    Eardley I, Ellis P, Boolell M, Wulff M. Onset and duration of action of sildenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol 2002; 53 (Suppl. 1): 61S65
  • 33
    Montorsi F, Maga T, Strambi LF et al. Sildenafil taken at bedtime significantly increases nocturnal erections: results of a placebo-controlled study. Urology 2000; 56: 906911
  • 34
    Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78: 257261
  • 35
    Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 13971404
  • 36
    Waldhauser M, Schramek P. Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction. J Urol 1988; 140: 525527
  • 37
    Belkoff L, McCullough A, Goldstein I, DiDonato K, Trask B, Bowden CH. An open-label, long-term evaluation of the safety and tolerability of avanafil in males with erectile dysfunction. J Sex Med 2011; 8: S396
  • 38
    Goldstein I, McCullough AR, Jones LA et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with generalized erectile dysfunction. J Sex Med 2012; 9: 11221133
  • 39
    Goldstein I, Jones LA, Belkoff LH et al. Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes. Mayo Clin Proc; in press
  • 40
    Mulhall JP, Moul JW, Wang R et al. A phase III, placebo-controlled study of the safety and efficacy of avanafil in the treatment of erectile dysfunction following bilateral, nerve-sparing radical prostatectomy. J Sex Med 2012; 9: S4243
  • 41
    Hellstrom JG, Freier MT, Serefoglu EC et al. Onset of action and time to efficacy of avanafil, a novel, rapid-onset PDE5 inhibitor in men with mild to severe erectile dysfunction: data from phase 2 and phase 3 clinical trails presented at the American Urological Association (AUA) Annual Meeting; May 19–23, 2012; Atlanta, GA. Poster #MP-53
  • 42
    Hellstrom WJ, Gittelman M, Karlin G et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763771
  • 43
    Brock GB, McMahon CG, Chen KK et al. Efficacy and safety of tadalafil in the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 13321336
  • 44
    Carson CC, Rajfer J, Eardley I et al. The efficacy and safety of tadalafil: an update. Br J Urol Int 2004; 93: 12761281
  • 45
    Mulhall JP, Burnett AL, McVary KT et al. Efficacy and safety of avanafil, a next-generation, phosphodiesterase type 5 inhibitor for the treatment of men with erectile dysfunction: data from phase 2 and 3 studies in difficult-to-treat populations. Presented at the American Urological Association (AUA) Annual Meeting; May 19–23, 2012; Atlanta, GA. Oral presentation